Skip To Main Content
Yinbiao Cao on Muck Rack

Yinbiao Cao

As seen in: Nature, Frontiers in Immunology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Yinbiao

Contact Yinbiao, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Ferritin heavy chain 1 expression is correlated with plasma cell exhaustion and acts as a prognostic correlative marker in hepatocellular carcinoma

|
By Yingwei Pan, Xiangfei Meng, Weizheng Liu, Hangyu Zhang, Qiang Yu, Yinbiao Cao, Jie Zhao, Weidong Duan, Haowen Tang, Zhanyu Yang
| Frontiers in Immunology
Abstract Background: Immunotherapy has emerged as a breakthrough in cancer treatment; however, the functional status of B lineage cells within the tumor microenvironment (TME) remains poorly characterized. Objective: This study systematically profiles the heterogeneity and dysfunctional exhausted state of plasma cells in the hepatocellular carcinoma (HCC) TME, and screens molecular signatures correlated with plasma cell exhaustion.
Open in Who Shared Issue with article?

Sintilimab (PD-1 inhibitor) plus lenvatinib as conversion therapy followed by sequential surgery (SILENSES) for advanced unresectable hepatocellular carcinoma: a phase II, expansion trial

|
By Shichun Lu, Wenwen Zhang, Junfeng Li, Ze Zhang, Bingyang Hu, Xuerui Li, Zhijun Wang, Huiyi Ye, Baolin Qu, Yu Li, Guangyu Ma, Tao Wan, Zhe Liu, Bing Liu, Haowen Tang, Xiao Zhao, Liru Pan, Jing Yuan, Ruiqing Chen, Xiangbing Bian, Yinbiao Cao, Zhanbo Wang, Yinzhe Xu
| Nature Verified
Abstract Our previous findings demonstrated the promising antitumor activity and manageable safety of sintilimab-lenvatinib conversion therapy. The current study aimed to evaluate long-term survival outcomes in patients with unresectable hepatocellular carcinoma (HCC) who underwent sequential surgical resection after successful conversion therapy. In this prospective, single-arm, expansion, phase II trial, patients with unresectable HCC received lenvatinib plus sintilimab conversion therapy.
Open in Who Shared Issue with article?
See all 2 articles